Unravelling the relationship between degree of disorder and the dissolution behavior of milled glibenclamide.
暂无分享,去创建一个
Thomas Rades | Timo Laaksonen | Jaakko Aaltonen | C. Strachan | T. Rades | J. Aaltonen | Leena Peltonen | T. Laaksonen | P. T. Mah | L. Peltonen | Clare J Strachan | Pei T Mah
[1] C. Strachan,et al. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[2] Bernard Van Eerdenbrugh,et al. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation--classification and comparison with crystallization tendency from undercooled melts. , 2010, Journal of pharmaceutical sciences.
[3] J. Rantanen,et al. Assessment of crystalline disorder in cryo-milled samples of indomethacin using atomic pair-wise distribution functions. , 2011, International journal of pharmaceutics.
[4] L Yu,et al. Amorphous pharmaceutical solids: preparation, characterization and stabilization. , 2001, Advanced drug delivery reviews.
[5] H. Siesler,et al. Conformational polymorphism of the antidiabetic drug chlorpropamide , 2012 .
[6] K. Kawakami,et al. Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. , 2009, Journal of pharmaceutical sciences.
[7] Jonathan C Burley,et al. Investigating the recrystallization behavior of amorphous paracetamol by variable temperature Raman studies and surface Raman mapping. , 2012, Molecular pharmaceutics.
[8] Siegfried Wartewig,et al. Pharmaceutical applications of Mid-IR and Raman spectroscopy. , 2005, Advanced drug delivery reviews.
[9] R. Tan,et al. Dissolution enhancement of indomethacin via amorphization using co-milling and supercritical co-precipitation processing , 2013 .
[10] C. Pouton,et al. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[11] T. Rades,et al. Thermal degradation of amorphous glibenclamide. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[12] Ashwini Nangia,et al. Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals , 2011 .
[13] Chandan Bhugra,et al. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. , 2008, Journal of pharmaceutical sciences.
[14] Jukka Rantanen,et al. In situ measurement of solvent-mediated phase transformations during dissolution testing. , 2006, Journal of pharmaceutical sciences.
[15] C. Strachan,et al. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. , 2013, International journal of pharmaceutics.
[16] V. Caron,et al. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. , 2011, Molecular pharmaceutics.
[17] Thomas Rades,et al. Correlating thermodynamic and kinetic parameters with amorphous stability. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[18] E. Sallam,et al. Preparation and characterization of a new polymorphic form and a solvate of glibenclamide. , 1997, Acta pharmaceutica Hungarica.
[19] C. Strachan,et al. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[20] R. Suryanarayanan,et al. Effect of Preparation Method on Physical Properties of Amorphous Trehalose , 2004, Pharmaceutical Research.
[21] Christel A. S. Bergström,et al. Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development. , 2011, Molecular pharmaceutics.
[22] G. Zografi,et al. The Quantitative Analysis of Crystallinity Using FT-Raman Spectroscopy , 1998, Pharmaceutical Research.
[23] M. Suleiman,et al. Isolation and physicochemical characterization of solid forms of glibenclamide , 1989 .
[24] C. Strachan,et al. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[25] J. Rantanen,et al. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[26] M. Descamps,et al. Solid State Amorphization of Pharmaceuticals , 2009 .
[27] Bernard Van Eerdenbrugh,et al. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. , 2010, Journal of pharmaceutical sciences.
[28] Sergey Vyazovkin,et al. Crystallization kinetics of amorphous nifedipine studied by model-fitting and model-free approaches. , 2003, Journal of pharmaceutical sciences.
[29] S. Boerrigter,et al. Investigation of the Milling-Induced Thermal Behavior of Crystalline and Amorphous Griseofulvin , 2010, Pharmaceutical Research.
[30] R. Pinal,et al. The nature of crystal disorder in milled pharmaceutical materials , 2008 .
[31] C. Strachan,et al. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[32] R. Pinal,et al. Process induced disorder in crystalline materials: differentiating defective crystals from the amorphous form of griseofulvin. , 2008, Journal of pharmaceutical sciences.
[33] N. Trasi,et al. Mechanically Induced Amorphization of Drugs: A Study of the Thermal Behavior of Cryomilled Compounds , 2012, AAPS PharmSciTech.
[34] Robin Taylor,et al. Mercury: visualization and analysis of crystal structures , 2006 .
[35] Christel A.S. Bergström,et al. Early drug development predictions of glass-forming ability and physical stability of drugs. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[36] Cornelia M Keck,et al. Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. , 2004, Journal of biotechnology.
[37] Mo Li,et al. Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs , 2009 .
[38] M. B. James,et al. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. , 2005, Journal of pharmaceutical sciences.
[39] C. Strachan,et al. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods. , 2011, International journal of pharmaceutics.
[40] Z. Iqbal,et al. Spectroscopic and X-Ray Diffraction Study of Structural Disorder in Cryomilled and Amorphous Griseofulvin , 2011 .
[41] A. Fahr,et al. Drug delivery strategies for poorly water-soluble drugs , 2007, Expert opinion on drug delivery.
[42] M. Descamps,et al. Grinding of drugs with pharmaceutical excipients at cryogenic temperatures , 2007 .
[43] G. Regdon,et al. Quantitative Determination of Crystallinity of α-Lactose Monohydrate by DSC , 2002 .
[44] K. Chrissafis,et al. Crystallization kinetics of amorphous , 2003 .